Atea Pharmaceuticals, Inc.

Quick facts

Phase 3 pipeline

• Bemnifosbuvir (BEM) · Virology; Infectious Disease
  Bemnifosbuvir is a nucleoside analog that inhibits viral RNA-dependent RNA polymerase, blocking replication of RNA viruses.
• Bemnifosbuvir-Ruzasvir · Infectious Disease / Virology
  Bemnifosbuvir is a nucleoside analog that inhibits hepatitis C virus (HCV) RNA-dependent RNA polymerase, while ruzasvir is an NS5A inhibitor that blocks viral protein function and replication.

Phase 1 pipeline

• AT-527 and Probenecid · Infectious Disease
  AT-527 is a nucleoside analog that inhibits the RNA-dependent RNA polymerase of SARS-CoV-2, and Probenecid is a uricosuric agent that increases the renal excretion of uric acid.
• AT-527 fasted
• AT-527 fed
• AT-527 single dose · Infectious Disease
  AT-527 is a nucleoside analog that inhibits viral RNA-dependent RNA polymerase, thereby blocking viral replication.
• Period 2: carbamazepine

Competitive intelligence

For the full portfolio CI brief — phase mix, recent regulatory actions, upcoming PDUFA dates, patent timeline, class-overlap with competitors:

• Atea Pharmaceuticals, Inc. portfolio CI brief
• Atea Pharmaceuticals, Inc. pipeline updates RSS